Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B-LONG trial

Haemophilia. 2023 Jan;29(1):404-407. doi: 10.1111/hae.14727. Epub 2022 Dec 22.

Authors

Robert F Sidonio Jr¹, Sandra Casiano², Aletta Falk³, Arman Altincatal², Suresh Katragadda⁴, Elena Santagostino⁵, Jerzy Windyga⁶

Affiliations

¹ Aflac Cancer and Blood Disorders, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
² Sanofi, Cambridge, Massachusetts, USA.
³ Swedish Orphan Biovitrum AB, Stockholm, Sweden.
⁴ Sanofi, Waltham, Massachusetts, USA.
⁵ Swedish Orphan Biovitrum AG, Basel, Switzerland.
⁶ Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

PMID: 36548200
DOI: 10.1111/hae.14727

No abstract available

Keywords: clinical study; factor IX; factor IX Fc fusion protein; haemophilia B; pharmacokinetics.

Publication types

Clinical Trial, Phase III
Letter

MeSH terms

Factor IX* / pharmacokinetics
Factor IX* / therapeutic use
Hemophilia B* / drug therapy
Humans
Immunoglobulin Fc Fragments / therapeutic use
Recombinant Fusion Proteins / pharmacokinetics
Recombinant Fusion Proteins / therapeutic use

Substances

Factor IX
factor IX Fc fusion protein
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins